Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tigilanol Tiglate in Advanced Soft Tissue Sarcoma
NCT05755113Phase 2Recruiting
- Sponsor
- QBiotics Group Limited
- Start
- Apr 2023
- Primary completion
- Jan 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tigilanol tiglate in soft tissue sarcoma (STS), sponsored by QBiotics Group Limited. Started Apr 2023; status: recruiting.
02
Drugs
tigilanol tiglate
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05755113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05755113.